Sébastien Delhaye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sébastien Delhaye has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Barbara Bardoni
Institut de Pharmacologie Moléculaire et Cellulaire CNRS UMR7275 - Inserm U1323 -Université Côte d’Azur 660 route des Lucioles – Sophia Antipolis 06560 Valbonne
5 shared publications Marielle Jarjat
Université Côte d'Azur, CNRS, Institute of Molecular and Cellular Pharmacology, 06560 Valbonne Sophia Antipolis, France
3 shared publicationsSara Castagnola
Université Côte d'Azur, CNRS, Institute of Molecular and Cellular Pharmacology, 06560 Valbonne Sophia Antipolis, France
3 shared publications- Thomas Maurin
Department of Developmental Biology, Sloan-Kettering Institute, New York, New York 10065, USA
3 shared publications - Enzo Lalli
Institut de Pharmacologie Moléculaire et Cellulaire CNRS UMR7275, Inserm U1323, Université Côte d’Azur, 06560 Valbonne, France
2 shared publications Frédéric Brau
Université Côte d'Azur, CNRS, Institute of Molecular and Cellular Pharmacology, 06560 Valbonne Sophia Antipolis, France
2 shared publications
Latest Publications
- 6 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Rôle de la phosphodiestérase 2A dans la physiopathologie du syndrome de l’X fragile
Le Syndrome de l’X Fragile (SXF) est la forme la plus fréquente de déficience intellectuelle héréditaire. Le phénotype des patients SXF est complexe. En effet, ils présentent aussi des traits autistiques, de l’hyperactivité et un déficit de l’attention. Au niveau du cerveau, le phénotype majeur est la présence d’épines dendritiques plus nombreuses, plus longues et plus fines. Ces anomalies morphologiques sont associées à des formes altérées de plasticité synaptique chez le modèle murin de SXF, la souris Fmr1-KO. Le SXF est causé par l’expansion (plus de 200 fois) du triplet nucléotidique CGG dans le 5’UTR du gène Fragile X Mental Retardation 1 (FMR1). L’hyperméthylation de cette région du gène FMR1 et, surtout de son promoteur, induit la suppression de l’expression de FMR1 et donc l’absence de la protéine FMRP codé par ce dernier. Une expansion entre 50 et 200 fois du triplet est considérée comme une prémutation et est associée à deux autres maladies : le syndrome du tremblement-ataxie lié au X Fragile (FXTAS), une maladie neurodégénérative, et l’insuffisance ovarienne liée à la prémutation de l’X Fragile (FXPOI). FMRP se lie à l’ARNm et est impliquée dans la régulation de plusieurs étapes du métabolisme de l’ARN, en particulier dans la modulation de la traduction de plusieurs protéines synaptiques. Aucune thérapie n’est aujourd’hui disponible pour traiter les patients atteints de SXF. J’ai montré que FMRP module l’expression de la Phosphodiesterase 2A (PDE2A) au niveau synaptique. PDE2A est une enzyme impliquée dans la dégradation de l’AMPc et du GMPc, deux seconds messagers qui jouent un rôle critique dans le développement et la différenciation des neurones. Quand FMRP est absente, le niveau et l’activité de PDE2A sont augmentés et, en conséquence, les niveaux d’AMPc et de GMPc sont réduits dans le cortex et l’hippocampe. J’ai montré que le traitement avec un inhibiteur spécifique de la PDE2A, le BAY 60-7550, rétablit les déficits sociaux chez les souris Fmr1-KO jeunes et adolescentes, la morphologie anormale des épines dendritiques et la Long Term Depression mGluR-dépendante exagérée. Afin de valider par une approche génétique que la réduction du niveau (et de l’activité) de la PDE2A pourrait avoir un rôle thérapeutique pour le SXF, j’ai croisé la lignée Pde2a+/- avec les souris Fmr1-KO et analysé le phénotype comportemental, la morphologie neuronale et les voies de signalisation liées à l’AMPc et au GMPc dans l’hippocampe et le cortex des souris générées par ce croisement. En effet, j’ai pu montrer que les animaux Fmr1-KOxPde2a+/- ont un phénotype sociocognitif normal comparé aux les animaux Fmr1-KO et Pde2a+/-. En effet, les souris Pde2a+/- ont un comportement très similaire à celui des animaux Fmr1-KO même si les altérations moléculaires dans le cerveau apparaissent inversées comparées à celles des souris Fmr1-KO. Dans leur ensemble, mes résultats montrent l’importance des voies AMPc et GMPc qui dépendent de PDE2A dans la pathophysiologie de FXS et dans le neurodéveloppement. En effet, j’ai identifié un nouveau modèle de maladies du développement du cerveau dû à la réduction du niveau d’activité de Pde2a+/-. Dans la première partie de mon doctorat, j’ai contribué à l’identification de la morphologie des neurones corticaux obtenus à partir d’un modèle murin de FXTAS.
- 6 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Rôle de la phosphodiestérase 2A dans la physiopathologie du syndrome de l’X fragile
Le Syndrome de l’X Fragile (SXF) est la forme la plus fréquente de déficience intellectuelle héréditaire. Le phénotype des patients SXF est complexe. En effet, ils présentent aussi des traits autistiques, de l’hyperactivité et un déficit de l’attention. Au niveau du cerveau, le phénotype majeur est la présence d’épines dendritiques plus nombreuses, plus longues et plus fines. Ces anomalies morphologiques sont associées à des formes altérées de plasticité synaptique chez le modèle murin de SXF, la souris Fmr1-KO. Le SXF est causé par l’expansion (plus de 200 fois) du triplet nucléotidique CGG dans le 5’UTR du gène Fragile X Mental Retardation 1 (FMR1). L’hyperméthylation de cette région du gène FMR1 et, surtout de son promoteur, induit la suppression de l’expression de FMR1 et donc l’absence de la protéine FMRP codé par ce dernier. Une expansion entre 50 et 200 fois du triplet est considérée comme une prémutation et est associée à deux autres maladies : le syndrome du tremblement-ataxie lié au X Fragile (FXTAS), une maladie neurodégénérative, et l’insuffisance ovarienne liée à la prémutation de l’X Fragile (FXPOI). FMRP se lie à l’ARNm et est impliquée dans la régulation de plusieurs étapes du métabolisme de l’ARN, en particulier dans la modulation de la traduction de plusieurs protéines synaptiques. Aucune thérapie n’est aujourd’hui disponible pour traiter les patients atteints de SXF. J’ai montré que FMRP module l’expression de la Phosphodiesterase 2A (PDE2A) au niveau synaptique. PDE2A est une enzyme impliquée dans la dégradation de l’AMPc et du GMPc, deux seconds messagers qui jouent un rôle critique dans le développement et la différenciation des neurones. Quand FMRP est absente, le niveau et l’activité de PDE2A sont augmentés et, en conséquence, les niveaux d’AMPc et de GMPc sont réduits dans le cortex et l’hippocampe. J’ai montré que le traitement avec un inhibiteur spécifique de la PDE2A, le BAY 60-7550, rétablit les déficits sociaux chez les souris Fmr1-KO jeunes et adolescentes, la morphologie anormale des épines dendritiques et la Long Term Depression mGluR-dépendante exagérée. Afin de valider par une approche génétique que la réduction du niveau (et de l’activité) de la PDE2A pourrait avoir un rôle thérapeutique pour le SXF, j’ai croisé la lignée Pde2a+/- avec les souris Fmr1-KO et analysé le phénotype comportemental, la morphologie neuronale et les voies de signalisation liées à l’AMPc et au GMPc dans l’hippocampe et le cortex des souris générées par ce croisement. En effet, j’ai pu montrer que les animaux Fmr1-KOxPde2a+/- ont un phénotype sociocognitif normal comparé aux les animaux Fmr1-KO et Pde2a+/-. En effet, les souris Pde2a+/- ont un comportement très similaire à celui des animaux Fmr1-KO même si les altérations moléculaires dans le cerveau apparaissent inversées comparées à celles des souris Fmr1-KO. Dans leur ensemble, mes résultats montrent l’importance des voies AMPc et GMPc qui dépendent de PDE2A dans la pathophysiologie de FXS et dans le neurodéveloppement. En effet, j’ai identifié un nouveau modèle de maladies du développement du cerveau dû à la réduction du niveau d’activité de Pde2a+/-. Dans la première partie de mon doctorat, j’ai contribué à l’identification de la morphologie des neurones corticaux obtenus à partir d’un modèle murin de FXTAS.
- Open Access
Defects in AMPAR trafficking and microglia activation underlie socio-cognitive deficits associated to decreased expression of Phosphodiesterase 2A
Phosphodiesterase 2A (PDE2A) is an enzyme involved in the homeostasis of cAMP and cGMP and is the most highly expressed PDE in human brain regions critical for socio-cognitive behavior. In cortex and hippocampus, PDE2A expression level is upregulated in Fmr1 -KO mice, a model of the Fragile X Syndrome (FXS), the most common form of inherited intellectual disability (ID) and autism spectrum disorder (ASD). Indeed, PDE2A translation is negatively modulated by FMRP, whose functional absence causes FXS. While the pharmacological inhibition of PDE2A has been associated to its pro-cognitive role in normal animals and in models of ID and ASD, homozygous PDE2A mutations have been identified in patients affected by ID, ASD and epilepsy. To clarify this apparent paradox about the role of PDE2A in brain development, we characterized here Pde2a +/− mice (homozygote animals being not viable) at the behavioral, cellular, molecular and electrophysiological levels. Pde2a +/− females display a milder form of the disorder with reduced cognitive performance in adulthood, conversely males show severe socio-cognitive deficits throughout their life. In males, these phenotypes are associated with microglia activation, elevated glutathione levels and increased externalization of GluR1 in CA1, producing reduced mGluR-dependent LTD. Overall, our results reveal molecular targets of the PDE2A-dependent pathway underlying socio-cognitive performance. These results clarify the mechanism of action of pro-cognitive drugs based on PDE2A inactivation, which have been shown to be promising therapeutic approaches for Alzheimer Disease, schizophrenia, FXS as well as other forms of ASD.
Open AccessDefects in AMPAR trafficking and microglia activation underlie socio-cognitive deficits associated to decreased expression of Phosphodiesterase 2A
Phosphodiesterase 2A (PDE2A) is an enzyme involved in the homeostasis of cAMP and cGMP and is the most highly expressed PDE in human brain regions critical for socio-cognitive behavior. In cortex and hippocampus, PDE2A expression level is upregulated in Fmr1 -KO mice, a model of the Fragile X Syndrome (FXS), the most common form of inherited intellectual disability (ID) and autism spectrum disorder (ASD). Indeed, PDE2A translation is negatively modulated by FMRP, whose functional absence causes FXS. While the pharmacological inhibition of PDE2A has been associated to its pro-cognitive role in normal animals and in models of ID and ASD, homozygous PDE2A mutations have been identified in patients affected by ID, ASD and epilepsy. To clarify this apparent paradox about the role of PDE2A in brain development, we characterized here Pde2a +/− mice (homozygote animals being not viable) at the behavioral, cellular, molecular and electrophysiological levels. Pde2a +/− females display a milder form of the disorder with reduced cognitive performance in adulthood, conversely males show severe socio-cognitive deficits throughout their life. In males, these phenotypes are associated with microglia activation, elevated glutathione levels and increased externalization of GluR1 in CA1, producing reduced mGluR-dependent LTD. Overall, our results reveal molecular targets of the PDE2A-dependent pathway underlying socio-cognitive performance. These results clarify the mechanism of action of pro-cognitive drugs based on PDE2A inactivation, which have been shown to be promising therapeutic approaches for Alzheimer Disease, schizophrenia, FXS as well as other forms of ASD.
- Top Cited PapersOpen Access
- 7 January 2021
- Published by Springer Nature in Molecular Psychiatry
- Vol. 26 (9) , 4570-4582
Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders
Phosphodiesterases (PDEs) are enzymes involved in the homeostasis of both cAMP and cGMP. They are members of a family of proteins that includes 11 subfamilies with different substrate specificities. Their main function is to catalyze the hydrolysis of cAMP, cGMP, or both. cAMP and cGMP are two key second messengers that modulate a wide array of intracellular processes and neurobehavioral functions, including memory and cognition. Even if these enzymes are present in all tissues, we focused on those PDEs that are expressed in the brain. We took into consideration genetic variants in patients affected by neurodevelopmental disorders, phenotypes of animal models, and pharmacological effects of PDE inhibitors, a class of drugs in rapid evolution and increasing application to brain disorders. Collectively, these data indicate the potential of PDE modulators to treat neurodevelopmental diseases characterized by learning and memory impairment, alteration of behaviors associated with depression, and deficits in social interaction. Indeed, clinical trials are in progress to treat patients with Alzheimer’s disease, schizophrenia, depression, and autism spectrum disorders. Among the most recent results, the application of some PDE inhibitors (PDE2A, PDE3, PDE4/4D, and PDE10A) to treat neurodevelopmental diseases, including autism spectrum disorders and intellectual disability, is a significant advance, since no specific therapies are available for these disorders that have a large prevalence. In addition, to highlight the role of several PDEs in normal and pathological neurodevelopment, we focused here on the deregulation of cAMP and/or cGMP in Down Syndrome, Fragile X Syndrome, Rett Syndrome, and intellectual disability associated with the CC2D1A gene.
- 7 January 2021
- Published by Springer Nature in Molecular Psychiatry
- Vol. 26 (9) , 4570-4582
Top Cited PapersOpen AccessRole of phosphodiesterases in the pathophysiology of neurodevelopmental disorders
Phosphodiesterases (PDEs) are enzymes involved in the homeostasis of both cAMP and cGMP. They are members of a family of proteins that includes 11 subfamilies with different substrate specificities. Their main function is to catalyze the hydrolysis of cAMP, cGMP, or both. cAMP and cGMP are two key second messengers that modulate a wide array of intracellular processes and neurobehavioral functions, including memory and cognition. Even if these enzymes are present in all tissues, we focused on those PDEs that are expressed in the brain. We took into consideration genetic variants in patients affected by neurodevelopmental disorders, phenotypes of animal models, and pharmacological effects of PDE inhibitors, a class of drugs in rapid evolution and increasing application to brain disorders. Collectively, these data indicate the potential of PDE modulators to treat neurodevelopmental diseases characterized by learning and memory impairment, alteration of behaviors associated with depression, and deficits in social interaction. Indeed, clinical trials are in progress to treat patients with Alzheimer’s disease, schizophrenia, depression, and autism spectrum disorders. Among the most recent results, the application of some PDE inhibitors (PDE2A, PDE3, PDE4/4D, and PDE10A) to treat neurodevelopmental diseases, including autism spectrum disorders and intellectual disability, is a significant advance, since no specific therapies are available for these disorders that have a large prevalence. In addition, to highlight the role of several PDEs in normal and pathological neurodevelopment, we focused here on the deregulation of cAMP and/or cGMP in Down Syndrome, Fragile X Syndrome, Rett Syndrome, and intellectual disability associated with the CC2D1A gene.
- Open Access
- 1 December 2019
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 18, 546-553
Reduction of Fmr1 mRNA Levels Rescues Pathological Features in Cortical Neurons in a Model of FXTAS
- 1 December 2019
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 18, 546-553
Open AccessReduction of Fmr1 mRNA Levels Rescues Pathological Features in Cortical Neurons in a Model of FXTAS
- Open Access
- 27 September 2018
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 11, 342
New Insights Into the Role of Cav2 Protein Family in Calcium Flux Deregulation in Fmr1-KO Neurons
Fragile X syndrome (FXS), the most common form of inherited intellectual disability (ID) and a leading cause of autism, results from the loss of expression of the Fmr1 gene which encodes the RNA-binding protein Fragile X Mental Retardation Protein (FMRP). Among the thousands mRNA targets of FMRP, numerous encode regulators of ion homeostasis. It has also been described that FMRP directly interacts with Ca2+ channels modulating their activity. Collectively these findings suggest that FMRP plays critical roles in Ca2+ homeostasis during nervous system development. We carried out a functional analysis of Ca2+ regulation using a calcium imaging approach in Fmr1-KO cultured neurons and we show that these cells display impaired steady state Ca2+ concentration and an altered entry of Ca2+ after KCl-triggered depolarization. Consistent with these data, we show that the protein product of the Cacna1a gene, the pore-forming subunit of the Cav2.1 channel, is less expressed at the plasma membrane of Fmr1-KO neurons compared to wild-type (WT). Thus, our findings point out the critical role that Cav2.1 plays in the altered Ca2+ flux in Fmr1-KO neurons, impacting Ca2+ homeostasis of these cells. Remarkably, we highlight a new phenotype of cultured Fmr1-KO neurons that can be considered a novel cellular biomarker and is amenable to small molecule screening and identification of new drugs to treat FXS.
- 27 September 2018
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 11, 342
Open AccessNew Insights Into the Role of Cav2 Protein Family in Calcium Flux Deregulation in Fmr1-KO Neurons
Fragile X syndrome (FXS), the most common form of inherited intellectual disability (ID) and a leading cause of autism, results from the loss of expression of the Fmr1 gene which encodes the RNA-binding protein Fragile X Mental Retardation Protein (FMRP). Among the thousands mRNA targets of FMRP, numerous encode regulators of ion homeostasis. It has also been described that FMRP directly interacts with Ca2+ channels modulating their activity. Collectively these findings suggest that FMRP plays critical roles in Ca2+ homeostasis during nervous system development. We carried out a functional analysis of Ca2+ regulation using a calcium imaging approach in Fmr1-KO cultured neurons and we show that these cells display impaired steady state Ca2+ concentration and an altered entry of Ca2+ after KCl-triggered depolarization. Consistent with these data, we show that the protein product of the Cacna1a gene, the pore-forming subunit of the Cav2.1 channel, is less expressed at the plasma membrane of Fmr1-KO neurons compared to wild-type (WT). Thus, our findings point out the critical role that Cav2.1 plays in the altered Ca2+ flux in Fmr1-KO neurons, impacting Ca2+ homeostasis of these cells. Remarkably, we highlight a new phenotype of cultured Fmr1-KO neurons that can be considered a novel cellular biomarker and is amenable to small molecule screening and identification of new drugs to treat FXS.
- 23 August 2018
- Published by Oxford University Press (OUP) in Cerebral Cortex
- Vol. 29 (8) , 3241-3252
Involvement of Phosphodiesterase 2A Activity in the Pathophysiology of Fragile X Syndrome
The fragile X mental retardation protein (FMRP) is an RNA-binding protein involved in translational regulation of mRNAs that play key roles in synaptic morphology and plasticity. The functional absence of FMRP causes the fragile X syndrome (FXS), the most common form of inherited intellectual disability and the most common monogenic cause of autism. No effective treatment is available for FXS. We recently identified the Phosphodiesterase 2A (Pde2a) mRNA as a prominent target of FMRP. PDE2A enzymatic activity is increased in the brain of Fmr1-KO mice, a recognized model of FXS, leading to decreased levels of cAMP and cGMP. Here, we pharmacologically inhibited PDE2A in Fmr1-KO mice and observed a rescue both of the maturity of dendritic spines and of the exaggerated hippocampal mGluR-dependent long-term depression. Remarkably, PDE2A blockade rescued the social and communicative deficits of both mouse and rat Fmr1-KO animals. Importantly, chronic inhibition of PDE2A in newborn Fmr1-KO mice followed by a washout interval, resulted in the rescue of the altered social behavior observed in adolescent mice. Altogether, these results reveal the key role of PDE2A in the physiopathology of FXS and suggest that its pharmacological inhibition represents a novel therapeutic approach for FXS.
- 23 August 2018
- Published by Oxford University Press (OUP) in Cerebral Cortex
- Vol. 29 (8) , 3241-3252
Involvement of Phosphodiesterase 2A Activity in the Pathophysiology of Fragile X Syndrome
The fragile X mental retardation protein (FMRP) is an RNA-binding protein involved in translational regulation of mRNAs that play key roles in synaptic morphology and plasticity. The functional absence of FMRP causes the fragile X syndrome (FXS), the most common form of inherited intellectual disability and the most common monogenic cause of autism. No effective treatment is available for FXS. We recently identified the Phosphodiesterase 2A (Pde2a) mRNA as a prominent target of FMRP. PDE2A enzymatic activity is increased in the brain of Fmr1-KO mice, a recognized model of FXS, leading to decreased levels of cAMP and cGMP. Here, we pharmacologically inhibited PDE2A in Fmr1-KO mice and observed a rescue both of the maturity of dendritic spines and of the exaggerated hippocampal mGluR-dependent long-term depression. Remarkably, PDE2A blockade rescued the social and communicative deficits of both mouse and rat Fmr1-KO animals. Importantly, chronic inhibition of PDE2A in newborn Fmr1-KO mice followed by a washout interval, resulted in the rescue of the altered social behavior observed in adolescent mice. Altogether, these results reveal the key role of PDE2A in the physiopathology of FXS and suggest that its pharmacological inhibition represents a novel therapeutic approach for FXS.